Citations

Clear

6729 citation(s) found for "Li, Mark".

Perioperative Compartment Syndrome of the Hand
Kies, Susan J., Danielson, David R., Dennison, David G., Warner, Mary E. , Warner, Mark A.

Mayo Clinic

Anesthesiology | October 19, 2004 | Volume: 101 | Issue: 5 | Pages: 1232-1234

10.1097/00000542-200411000-00027 | PMID 15505463 Get It

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
Rinehart, John J., Adjei, Alex A. , LoRusso, Patricia , Hecht, J. Randolph , Natale, Ronald B., Hamid, Oday , Varterasian, Mary , Asbury, Peggy, Kaldjian, Eric, Gulyas, Stephen, Mitchell, David, Herrera, Román, Chan, Anthony T.�C. , Waterhouse, David , Sebolt–Leopold, Judith S. , Meyer, Mark B.

Mayo Clinic

Journal of Clinical Oncology | October 14, 2004 | Volume: 22 | Issue: 22 | Pages: 4456-4462

10.1200/jco.2004.01.185 | PMID 15483017 Get It

Purpose This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor, CI-1040, in breast cancer, colon cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer. Patients and Methods Patients with advanced colorectal, NSCLC, breast, or pancreatic cancer received oral CI-1040 continuously at 800 mg bid. All patients had measurable disease at baseline, a performance status of 2 or less, and adequate bone marrow, liver, and renal function. Expression of pERK, pAkt, and Ki-67 was assessed in archived tumor specimens by quantitative immunohistochemistry. Results Sixty-seven patients with breast (n = 14), colon (n = 20), NSCLC (n = 18), and pancreatic (n = 15) cancer received a total of 194 courses of treatment (median, 2.0 courses; range, one to 14 courses). No complete or partial responses were observed. Stable disease (SD) lasting a median of 4.4 months (range, 4 to 18 months) was confirmed in eight patients (one breast, two colon, two pancreas, and three NSCLC patients). Treatment was well tolerated, with 81% of patients experiencing toxicities of grade 2 or less severity. Most common toxicities included diarrhea, nausea, asthenia, and rash. A mild association (P < .055) between baseline pERK expression in archived tumor specimens and SD was observed. Conclusion CI-1040 was generally well tolerated but demonstrated insufficient antitumor activity to warrant further development in the four tumors tested. PD 0325901, a second generation MEK inhibitor, has recently entered clinical development and, with significantly improved pharmacologic and pharmaceutical properties compared with CI-1040, it may better test the therapeutic potential of MEK inhibition in cancer.
Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease
Hlatky, Mark A. , Boothroyd, Derek , Melsop, Kathryn , Brooks, Maria M. , Mark, Daniel B. , Pitt, Bertram, Reeder, Guy S., Rogers, William J. , Ryan, Thomas J. , Whitlow, Patrick L., Wiens, Robert D., Mark, Daniel B

Mayo Clinic

Circulation | September 28, 2004 | Volume: 110 | Issue: 14 | Pages: 1960-1966

10.1161/01.cir.0000143379.26342.5c | PMID 15451795 Get It

Background— Coronary bypass surgery (CABG) and angioplasty (PTCA) have been compared in several randomized trials, but data about long-term economic and quality-of-life outcomes are limited. Methods and Results— Cost and quality-of-life data were collected prospectively from 934 patients who were randomized in the Bypass Angioplasty Revascularization Investigation (BARI) and followed up for 10 to12 years. CABG had 53% higher costs initially, but the gap closed to <5% during the first 2 years; after 12 years, the mean cumulative cost of CABG patients was $123 000 versus $120 750 for PTCA, yielding a cost-effectiveness ratio of $14 300/life-year added. CABG patients experienced significantly greater improvement in their physical functioning for the first 3 years but not in later follow-up. Recurrent angina substantially reduced all quality-of-life measures throughout follow-up. Cumulative costs were significantly higher among patients with diabetes, heart failure, and comorbid conditions and among women; costs also were increased by angina, by the number of revascularization procedures, and among patients who died. Conclusion— Early differences between CABG and PTCA in costs and quality of life were no longer significant at 10 to 12 years of follow-up. CABG was cost-effective as compared with PTCA for multivessel disease.
Changes in Tensile Strength of Cadaveric Human Fascia Lata After Implantation in a Rabbit Vagina Model
Walter, Andrew J., Morse, Abraham N. , Leslie, Kevin O., Zobitz, Mark E., Hentz, Joseph G. , Cornella, Jeffrey L.

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 169 | Issue: 5 | Pages: 1907-1910

10.1097/01.ju.0000061182.21353.a5 | PMID 12686871 Get It

Behind Schedule: Improving Access to Care for Children One Practice at a Time
Randolph, Greg D., Murray, Mark, Swanson, Jill A., Margolis, Peter A.

Mayo Clinic

Pediatrics | August 14, 2004 | Volume: 113 | Issue: 3 | Pages: e230-e237

10.1542/peds.113.3.e230 | PMID 14993582 Get It

Access to health care, the timely use of personal health services to achieve the best possible health outcomes, remains a fundamental problem for children in the United States. To date, research and interventions addressing children’s access to care have largely focused on policy-level features of the health care system (such as health insurance and geographic availability of providers) with some, although limited, success. Ultimately, access to health care implies entry into the health care system. Practice scheduling systems are the point of entry to primary care health services for children and thus directly determine access to care in pediatric and family medicine practices. Here we explore the rationale for improving access to care for children from an additional angle: through improving practice scheduling systems. It is our hypothesis that some of the most promising contemporary interventions to improve children’s access involve improving primary care scheduling systems. These approaches should complement successful policy-level interventions to improve access to care for children.
Diagnosis of Very Long Chain Acyl-Dehydrogenase Deficiency From an Infant's Newborn Screening Card
Magera, Mark J , Rinaldo, Piero, Seashore, Margretta R., Strauss, Arnold W. , Friedman, Alan H., Wood, John C.

Mayo Clinic

Pediatrics | August 13, 2004 | Volume: 108 | Issue: 1 | Pages: e19-e19

10.1542/peds.108.1.e19 | PMID 11433098 Get It

Very long chain fatty acid dehydrogenase (VLCAD) deficiency is a rare but treatable cause of cardiomyopathy, fatty liver, skeletal myopathy, pericardial effusions, ventricular arrhythmias, and sudden death. Unrecognized, VLCAD deficiency may be rapidly progressive and fatal, secondary to its cardiac involvement. Because early diagnosis improves outcome, we present a neonate with VLCAD deficiency in whom retrospective analysis of the newborn screening card revealed that a correct diagnosis could have been made by newborn screening using tandem mass spectrometry. Our patient demonstrated a classic neonatal course with transient hypoglycemia at birth, interpreted as culture-negative sepsis, followed by a quiescent period notable only for hypotonia and poor feeding. At 3 months, he presented with cardiorespiratory failure and pericardial effusions, requiring pericardiocentesis, tracheostomy, and prolonged mechanical ventilation. Plasma free-fatty acid and acylcarnitine profiles demonstrated small but significant elevations of C14:2, C14:1, C16, and C18:1 acylcarnitine species, findings consistent with a biochemical diagnosis of VLCAD deficiency. Enteral feeds were changed to Portagen formula with marked improvement in cardiac symptoms over several weeks. To confirm the biochemical diagnosis, molecular analysis was performed by analysis of genomic DNA on a blood sample of the patient. Sequencing analysis and delineation of VLCAD mutations were performed using polymerase chain reaction and genomic sequencing. The patient was heterozygous for 2 different disease-causing mutations at the VLCAD locus. The maternal mutation was a deletion of bp 842–3 in exon 8, causing a shift in the reading frame. The paternal mutation was G+1A in the consensus donor splice site after exon 1; this splice-site mutation would likely result in decreased mRNA. The likely consequence of these mutations is essentially a null phenotype. To determine whether this case could have been picked up by tandem mass spectrometry analysis at birth when the patient was asymptomatic, acylcarnitine analysis was performed on the patient's original newborn card (after obtaining parental consent, the original specimen was provided courtesy of Dr Kenneth Pass, Director, New York State Newborn Screening Program). The blood sample had been obtained at 1 week of age and stored at room temperature for 6 months and at 70°C thereafter for 18 months. Electrospray tandem mass spectrometry used a LC-MS/MS API 2000 operated in ion evaporation mode with the TurboIonSpray ionization probe source. The acylcarnitine profile obtained from the patient's original newborn card was analyzed 2 years after it was obtained. In comparison with a normal control, there was a significant accumulation of long chain acylcarnitine species, with a prominent peak of tetradecenoylcarnitine (C14:1), the most characteristic metabolic marker of VLCAD deficiency. This profile would have likely been even more significant if it had been analyzed at the time of collection, yet 2 years later is sufficient to provide strong biochemical evidence of the underlying disorder. Discussion. VLCAD was first discovered in 1992, and clinical experience with VLCAD deficiency has been accumulating rapidly. Indeed, the patients originally diagnosed with long chain acyl-CoA deficiency suffer instead from VLCAD deficiency. The phenotype of VLCAD deficiency is heterogeneous, ranging from catastrophic metabolic and cardiac failure in infancy to mild hypoketotic, hypoglycemia, and exertional rhabdomyolysis in adults. This case demonstrates that VLCAD deficiency could have been detected from the patient's own neonatal heel-stick sample. Most likely, a presymptomatic diagnosis would have avoided at least part of a lengthy and intensive prediagnosis hospitalization that had an estimated cost of $400 000. Although VLCAD is relatively rare, timely and correct diagnosis leads to dramatic recovery, so that detection by newborn screening could prevent the onset of arrhythmias, heart failure, metabolic insufficiency, and death. Fatty acid oxidation defects, including VLCAD deficiency, may account for as many as 5% of sudden infant death patients. Recent instrumentation advances have made automated tandem mass spectrometry of routine neonatal heel-stick samples technically feasible. Pilot studies have demonstrated an incidence of fatty acid oxidation defects, including short chain, medium chain, and very long chain acyl-CoA dehydrogenase deficiencies, of approximately 1/12 000. As a result, cost-benefit ratios for this approach should be systematically examined.
EVALUATION OF MICROPOROUS POLYSACCHARIDE HEMOSPHERES AS A NOVEL HEMOSTATIC AGENT IN OPEN PARTIAL NEPHRECTOMY: FAVORABLE EXPERIMENTAL RESULTS IN THE PORCINE MODEL
Murat, François-Joseph, Ereth, Mark H. , Dong, Yue , Piedra, Mark, Gettman, Matthew T., Murat, F.J., Dong, Yue

Mayo Clinic

Journal of Urology | August 12, 2004 | Volume: 172 | Issue: 3 | Pages: 1119-1122

10.1097/01.ju.0000136001.99920.97 | PMID 15311053 Get It

Clinical Evaluation and Management Strategy for Sexual Dysfunction in Men and Women
Hatzichristou, Dimitrios , Rosen, Raymond C., Broderick, Gregory A. , Clayton, Anita H. , Cuzin, B. , Derogatis, Leonard R. , Litwin, Mark S. , Meuleman, Eric, O’Leary, Michael P. , Quirk, Frances , Sadovsky, Richard, Seftel, Allen D.

Mayo Clinic

The Journal of Sexual Medicine | August 4, 2004 | Volume: 1 | Issue: 1 | Pages: 49-57

10.1111/j.1743-6109.2004.10108.x | PMID 16422983 Get It

ABSTRACT Introduction The optimal approach for identification and evaluation of the sexual problems in men and women in primary care or general medicine practice has not been consensed. Aim To provide recommendations/guidelines concerning state-of-the-art knowledge for clinical evaluation and management strategies in the evaluation and treatment of sexual dysfunction in men and women, emphasizing evidence-based medicine and a patient-centered framework. Methods An International Consultation in collaboration with the major urology and sexual medicine associations assembled over 200 multidisciplinary experts from 60 countries into 17 committees. Committee members established specific objectives and scopes for various male and female sexual medicine topics. The recommendations concerning state-of-the-art knowledge in the respective sexual medicine topic represent the opinion of experts from five continents developed in a process over a 2-year period. Concerning the Clinical Evaluation and Management Strategies Committee, there were 12 experts from five countries. Main Outcome Measure Expert opinion was based on grading of evidence-based medical literature, widespread internal committee discussion, public presentation and debate. Results Three concepts underlie sexual medicine management: (i) adoption of a patient-centered framework for evaluation and treatment; (ii) application of the principles of evidence-based medicine in diagnostic and treatment planning; and (iii) use of a unified management approach in men and women. When taken together, these three principles provide a balanced and integrated approach to sexual dysfunction management. Common algorithms for diagnosis and management of men and women with sexual dysfunction, brief sexual symptom checklists, basics in history and physical examination, indications for specialized referral and development of a follow-up strategy are presented. Conclusions More research is needed in understanding the role of evidence-based and patient-centered medicine in the clinical evaluation and management strategies of men and women with sexual dysfunction.
Primary Spinal Epidural Non-Hodgkin's Lymphoma
Lyons, Mark , Marsh, W. Richard , Kurtin, Paul J. , O’Neill, Brian Patrick

Mayo Clinic

Neurosurgery | July 30, 2004 | Volume: 30 | Issue: 5 | Pages: 675-680

10.1097/00006123-199205000-00004 | PMID 1584377 Get It